Alkermes plc (ALKS)
-NasdaqGS 32.84 
0.16(0.48%) May 24, 4:00PM EDT|After Hours
:
33.00 0.16 (0.49%) May 24, 5:00PM EDT
| Prev Close: | 33.00 |
|---|
| Open: | 32.64 |
|---|
| Bid: | 32.84 x 200 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 28.90 |
|---|
| Beta: | 1.21 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 32.00 - 34.30 |
|---|
| 52wk Range: | 14.82 - 34.30 |
|---|
| Volume: | 2,174,934 |
|---|
| Avg Vol (3m): | 1,358,310 |
|---|
| Market Cap: | 4.37B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.32 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alkermes downgraded by MKM PartnersBriefing.com(Fri, May 24)
- Reading the fine print turns initial Alkermes share loss into a gainat MarketWatch(Thu, May 23)
- Alkermes Earnings Beat Estimates, But Outlook Unclearat Investor's Business Daily(Thu, May 23)
- Biogen Submits Plegridy BLAZacks(Thu, May 23)
- Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care ConferenceBusiness Wire(Thu, May 23)
- Alkermes Stock Seesaws After Q4 Beat, Guidance Missat Investor's Business Daily(Thu, May 23)
- Alkermes Reports Earnings for Q4Zacks(Thu, May 23)
- Alkermes' CEO Discusses F4Q13 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 23)
- Alkermes posts 4Q profit as royalty payments riseAP(Thu, May 23)
- Alkermes Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Thu, May 23)
- Alkermes plc Earnings Call scheduled for 8:00 am ET todayCCBN(Thu, May 23)
- Q4 2013 Alkermes plc Earnings Release - Before Market OpenCCBN(Thu, May 23)
- Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides Financial ExpectationsBusiness Wire(Thu, May 23)
- ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal OffEDGAR Online(Thu, May 23)
- Alkermes Earnings Seen Rising, But Sales Uncertainat Investor's Business Daily(Wed, May 22)
Key Statistics
| Forward P/E (1 yr): | 22.19 |
|---|
| P/S (ttm): | 8.10 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Mar-14)
: | 1.13 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.29 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 0.37 |
|---|
Business Summary
Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizoph...
View More